New drug cocktail targets deadly bowel cancer mutation
Disease control
Recruiting now
This Phase 3 trial is testing whether a combination of two targeted drugs, tunlametinib and vemurafenib, can help people with a specific genetic mutation (BRAF V600E) in metastatic colorectal cancer. About 165 participants will be randomly assigned to receive either the drug comb…
Phase: PHASE3 • Sponsor: Shanghai Kechow Pharma, Inc. • Aim: Disease control
Last updated Jun 26, 2026 18:30 UTC